HERO demonstrated that Orgovyx was superior to Lupron in maintaining castration from day 29 up to week 48. Orgovyx also showed an almost a five-fold reduction in the risk of subsequent major cardiac events, a concern for men on Lupron.
FDA Approves An Oral Hormone Therapy (ADT)
The Food and Drug Administration has approved a new drug for men with advanced prostate cancer. The approval is for a first in kind hormone therapy (ADT) taken orally (by mouth) instead of the regular Lupron type injections we have been using.
Besides achieving and maintaining adequate levels of castration, Orgovyx was also superior to Lupron because it cut the incidence of serious heart events compared to Lupron.
